SRM to Launch Pharma Firm Soon

SRM to Launch Pharma Firm Soon

SRM University to commercialize US patented herbal diabetic drug in around six months time. The US Patent office granted patent for an herbal formulation for prevention and management of type-2 diabetes mellitus and vascular complications associated with the disease during December 2012.

A six member team of researchers led by Govind Prasad Dubey and comprising Aruna Agrawal, Nirupama Dubey, Shipra Dubey, Rajesh Dubey and Samamtsan Mercy Deborah invented the drug and secured the patent which was assigned to SRM University.

Dr. M Ponnavaiko, the Vice Chancellor of SRM University briefed that the company has so far invested around Rs 50 crore in setting up a research and development (R&D) centre for translational research, from basic research, with around 25 scientists working on various projects.

“A company has been registered with the name, SRM Pharma Industries and our focus would be on manufacturing and marketing herbal pharmaceutical products developed by us in the global market,” he said.

He added that there are plans to set up a manufacturing unit, which would be ready in the next six months to one year. “It will be coming up on the research park adjacent to SRM University. Once the facility is ready, the manufacturing of all its herbal products would be carried out from there”, he said.

While plans are yet to be ready for the manufacturing facility, the estimated investment for this would be Rs 25 crore, he added. The company has not decided on details including the time to launch the first product. However, plans for many of the factors related to the new company are yet to be finalised, he stated. "We will shortly file patent application for two more herbal drugs for menopause, cardiovascular and obesity problems," he said.

According to the US Patent office, the invention of a group of scientists from SRM “relates to the novel Ayurvedic formulation and to the process thereof for the prevention and management of dyslipidemia, atherosclerosis, obesity, and endothelial dysfunction in type-2 diabetes mellitus cases.

“The preparation of present invention is advantageous if used for the prevention and management of hyperglycemia, abnormal lipids, altered adipokines, elevated inflammatory cytokines, obesity, hyperhomocystinemia, hypertension and atherosclerosis involved with diabetic patients,” according to the United States Patent and Trademark Office.

This new venture of SRM has gained enormous recognition even at the inception stage. The management is sure to reach greater heights with many more novel ideas and research outcomes for there are many patent trials that are still underway.

Patent Details